Latest Smith, Kline & French Stories
RESEARCH TRIANGLE PARK, N.C., May 6 /PRNewswire-FirstCall/ -- GlaxoSmithKline plc (NYSE: GSK) today announced that it has entered into an agreement to divest full commercial rights to Wellbutrin XL(R) in the United States to Biovail International Laboratories SRL, a subsidiary of Biovail Corporation (NYSE, TSX: BVF), for $510 million (euro 340 million).
PHILADELPHIA, April 21 /PRNewswire-FirstCall/ -- On Wednesday, April 22, 2009 GlaxoSmithKline plc (NYSE: GSK) will announce its first quarter financial results for the three months ended March 31, 2009.
British pharmaceutical giant GlaxoSmithKline said Monday it agreed to purchase skin-products producer Stiefel Laboratories for $2.9 billion. The deal includes the assumption of $400 million of Stiefel's debt, but will add a robust development pipeline to GlaxoSmithKline's product line, the company said in a statement.
Stiefel, the world's largest independent dermatology company, acquired by GSK in deal valued at up to $3.6 billion New global business will have combined revenues of approximately $1.5 billion and robust new product pipeline Significant step forward to grow and diversify GSK's business, providing immediate new revenue and synergy opportunities LONDON, April 20 /PRNewswire-FirstCall/ -- GlaxoSmithKline plc (NYSE: GSK) and Stiefel Laboratories Inc.
LONDON, April 16 /PRNewswire-FirstCall/ -- Pharmaceutical companies GlaxoSmithKline and Pfizer today announced an "innovative agreement" to pool their HIV assets creating a new world-leading, specialist HIV company. The deal will see the drug giants combine their existing HIV product and their pipelines with GSK holding 85% of the company and Pfizer 15%. The deal will be marginally dilutive to GSK earnings in the first two years but in a video interview Group CEO Andrew Witty said...
- Creates a new focused HIV business with the independence and sustainability to deliver significant improvements in treatment, access and shareholder value - Renews focus on HIV with industry-leading pipeline to deliver more new HIV treatments - Equity split of 85% GSK and 15% Pfizer LONDON and PHILADELPHIA, April 16 /PRNewswire-FirstCall/ -- GlaxoSmithKline plc (NYSE: GSK) and Pfizer Inc (NYSE: PFE) today announced they have entered into an agreement to create a new world-leading HIV...
Fluticasone Propionate Nasal Spray (FLONASE(R)) will be the first product marketed under this arrangement MASON, Ohio, March 11 /PRNewswire/ -- Prasco Laboratories, announced today it has entered into a marketing and distribution agreement with GlaxoSmithKline (NYSE: GSK).
According to the head of British pharmaceutical giant GlaxoSmithKline, the company will begin sharing knowledge of patented treatments, and will cut prices for medication in developing nations.
Industry Leaders Team up to Drive Performance Improvements World Wide LONDON, Ontario, Feb.
LONDON, February 5 /PRNewswire-FirstCall/ -- In a video interview Andrew Witty, GlaxoSmithKline CEO, described the pharmaceutical group's results as "robust" in a year that was "always going to be challenging". GSK also announced that it will cease providing EPS guidance, to allow a focus on longer term strategic goals. Describing 2008 as a strategic turning point for GSK Mr Witty said: "We started to make very clear what it would take to really make this company strong over the...
- To play, gamble.
- To impose upon; delude; trick; humbug; also, to joke; chaff.
- A deceitful game or trick; trickery; humbug; nonsense.